Novelion Therapeutics, Inc. (NASDAQ: NVLN) Starts Presentation at 29th Annual Roth Conference
Novelion Therapeutics (NASDAQ: NVLN) is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. For more information, visit the company’s website at www.novelion.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press…







